OpenAccessBelV2, PascalFrancis, Corpus, bibRecord, 000064

Robotic-Assisted Laparoscopic Extended Pelvic Lymph Node Dissection for Prostate Cancer : Surgical Technique and Experience with the First 99 Cases. Commentaries

Identifieur interne : 000064 ( PascalFrancis/Corpus ); précédent : 000063; suivant : 000065

Robotic-Assisted Laparoscopic Extended Pelvic Lymph Node Dissection for Prostate Cancer : Surgical Technique and Experience with the First 99 Cases. Commentaries

Auteurs : Antje Feicke ; Martin Baumgartner ; Scherwin Talimi ; Daniel Max Schmid ; Hans-Helge Seifert ; Michael Müntener ; Markus Fatzer ; Tullio Sulser ; Rdto T. Strebel ; Alexandre Mottrie ; Karim Touijer

Source :

European urology [ 0302-2838 ] ; 2009.

RBID : Pascal:09-0161374

Descripteurs français

Pascal (Inist)
- Cancer de la prostate, Robotique, Télémédecine, Tumeur de la prostate, Laparoscopie, Ganglion pelvien, Lymphadénectomie, Chirurgie, Technique, Complication, Endoscopie, Ganglion lymphatique, Excision, Méthodologie, Procédure, Néphrologie, Urologie, Traitement.

English descriptors

KwdEn :
- Complication, Endoscopy, Excision, Laparoscopy, Lymph node, Lymphadenectomy, Methodology, Nephrology, Pelvic ganglion, Procedure, Prostate cancer, Prostate tumor, Robotics, Surgery, Technique, Telemedicine, Treatment, Urology.

Abstract

Background: To date, there is still a paucity of data in the literature on robotic-assisted laparoscopic extended pelvic lymph node dissection (RALEPLND) in patients with prostate cancer. Objective: To assess the technical feasibility of RALEPLND and to present our surgical technique. Design, setting, and participants: From April 2006 to March 2008, we performed RALEPLND in 99 patients prior to robotic-assisted laparoscopic radical prostatectomy. Indications for RALEPLND were a prostate-specific antigen (PSA) >10 ng/ml or a preoperative Gleason score >7. The data were evaluated retrospectively. Surgical procedure: The transperitoneal approach was used in all cases. In order to gain optimal access to the common iliac bifurcation, the five trocars were placed in a more cephalad position than in patients undergoing radical prostatectomy without RALEPLND. After identification of important landmarks, the lymphatics covering the external iliac vein, the obturator lymphatic packet, and the lymphatics overlying the internal iliac artery were removed on both sides. Measurements: The total lymph node yield, the frequency of lymph node metastases, and the complication rate. Results and limitations: The median patient age was 64 yr (range: 45-78). The median preoperative PSA level was 7.7 ng/ml (range: 1.5-84.6). The median number of lymph nodes harvested was 19 (range: 8-53). In 16 patients (16%), we found lymph node metastasis. Complications occurred in seven patients (7%). Conclusions: RALEPLND is feasible, and its lymph node yield is well in the range of open series. The robotic-assisted laparoscopic approach in itself does not seem to limit a surgeon's ability to perform a complete extended pelvic lymph node dissection.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 0302-2838`
A02	`01`			`@0 EUURAV`
A03		`1`		`@0 Eur. urol.`
A05				`@2 55`
A06				`@2 4`
A08	`01`	`1`	`ENG`	`@1 Robotic-Assisted Laparoscopic Extended Pelvic Lymph Node Dissection for Prostate Cancer : Surgical Technique and Experience with the First 99 Cases. Commentaries`
A11	`01`	`1`		`@1 FEICKE (Antje)`
A11	`02`	`1`		`@1 BAUMGARTNER (Martin)`
A11	`03`	`1`		`@1 TALIMI (Scherwin)`
A11	`04`	`1`		`@1 SCHMID (Daniel Max)`
A11	`05`	`1`		`@1 SEIFERT (Hans-Helge)`
A11	`06`	`1`		`@1 MÜNTENER (Michael)`
A11	`07`	`1`		`@1 FATZER (Markus)`
A11	`08`	`1`		`@1 SULSER (Tullio)`
A11	`09`	`1`		`@1 STREBEL (Rdto T.)`
A11	`10`	`1`		`@1 MOTTRIE (Alexandre) @9 comment.`
A11	`11`	`1`		`@1 TOUIJER (Karim) @9 comment.`
A14	`01`			`@1 Department of Urology, University Hospital Zürich, University of Zürich @2 Zürich @3 CHE @Z 1 aut. @Z 2 aut. @Z 3 aut. @Z 4 aut. @Z 5 aut. @Z 6 aut. @Z 7 aut. @Z 8 aut. @Z 9 aut.`
A14	`02`			`@1 O.L.V. Clinic @2 Aalst @3 BEL @Z 10 aut.`
A14	`03`			`@1 Department of Surgery, Urology Service, Memorial Sioan-Kettering Cancer Center @2 New York @3 USA @Z 11 aut.`
A20				`@1 876-884`
A21				`@1 2009`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 16847 @5 354000187052290140`
A44				`@0 0000 @1 © 2009 INIST-CNRS. All rights reserved.`
A45				`@0 36 ref.`
A47	`01`	`1`		`@0 09-0161374`
A60				`@1 P @3 AR @3 CT`
A61				`@0 A`
A64	`01`	`1`		`@0 European urology`
A66	`01`			`@0 GBR`
C01	`01`		`ENG`	@0 Background: To date, there is still a paucity of data in the literature on robotic-assisted laparoscopic extended pelvic lymph node dissection (RALEPLND) in patients with prostate cancer. Objective: To assess the technical feasibility of RALEPLND and to present our surgical technique. Design, setting, and participants: From April 2006 to March 2008, we performed RALEPLND in 99 patients prior to robotic-assisted laparoscopic radical prostatectomy. Indications for RALEPLND were a prostate-specific antigen (PSA) >10 ng/ml or a preoperative Gleason score >7. The data were evaluated retrospectively. Surgical procedure: The transperitoneal approach was used in all cases. In order to gain optimal access to the common iliac bifurcation, the five trocars were placed in a more cephalad position than in patients undergoing radical prostatectomy without RALEPLND. After identification of important landmarks, the lymphatics covering the external iliac vein, the obturator lymphatic packet, and the lymphatics overlying the internal iliac artery were removed on both sides. Measurements: The total lymph node yield, the frequency of lymph node metastases, and the complication rate. Results and limitations: The median patient age was 64 yr (range: 45-78). The median preoperative PSA level was 7.7 ng/ml (range: 1.5-84.6). The median number of lymph nodes harvested was 19 (range: 8-53). In 16 patients (16%), we found lymph node metastasis. Complications occurred in seven patients (7%). Conclusions: RALEPLND is feasible, and its lymph node yield is well in the range of open series. The robotic-assisted laparoscopic approach in itself does not seem to limit a surgeon's ability to perform a complete extended pelvic lymph node dissection.
C02	`01`	`X`		`@0 002B14D02`
C02	`02`	`X`		`@0 002B20B02`
C03	`01`	`X`	`FRE`	`@0 Cancer de la prostate @2 NM @5 01`
C03	`01`	`X`	`ENG`	`@0 Prostate cancer @2 NM @5 01`
C03	`01`	`X`	`SPA`	`@0 Cáncer de la próstata @2 NM @5 01`
C03	`02`	`X`	`FRE`	`@0 Robotique @5 02`
C03	`02`	`X`	`ENG`	`@0 Robotics @5 02`
C03	`02`	`X`	`SPA`	`@0 Robótica @5 02`
C03	`03`	`X`	`FRE`	`@0 Télémédecine @5 03`
C03	`03`	`X`	`ENG`	`@0 Telemedicine @5 03`
C03	`03`	`X`	`SPA`	`@0 Telemedicina @5 03`
C03	`04`	`X`	`FRE`	`@0 Tumeur de la prostate @2 NM @5 04`
C03	`04`	`X`	`ENG`	`@0 Prostate tumor @2 NM @5 04`
C03	`04`	`X`	`SPA`	`@0 Tumor prostata @2 NM @5 04`
C03	`05`	`X`	`FRE`	`@0 Laparoscopie @5 05`
C03	`05`	`X`	`ENG`	`@0 Laparoscopy @5 05`
C03	`05`	`X`	`SPA`	`@0 Laparoscopia @5 05`
C03	`06`	`X`	`FRE`	`@0 Ganglion pelvien @5 06`
C03	`06`	`X`	`ENG`	`@0 Pelvic ganglion @5 06`
C03	`06`	`X`	`SPA`	`@0 Ganglio pelviano @5 06`
C03	`07`	`X`	`FRE`	`@0 Lymphadénectomie @5 08`
C03	`07`	`X`	`ENG`	`@0 Lymphadenectomy @5 08`
C03	`07`	`X`	`SPA`	`@0 Linfadenectomía @5 08`
C03	`08`	`X`	`FRE`	`@0 Chirurgie @5 09`
C03	`08`	`X`	`ENG`	`@0 Surgery @5 09`
C03	`08`	`X`	`SPA`	`@0 Cirugía @5 09`
C03	`09`	`X`	`FRE`	`@0 Technique @5 11`
C03	`09`	`X`	`ENG`	`@0 Technique @5 11`
C03	`09`	`X`	`SPA`	`@0 Técnica @5 11`
C03	`10`	`X`	`FRE`	`@0 Complication @5 12`
C03	`10`	`X`	`ENG`	`@0 Complication @5 12`
C03	`10`	`X`	`SPA`	`@0 Complicación @5 12`
C03	`11`	`X`	`FRE`	`@0 Endoscopie @5 17`
C03	`11`	`X`	`ENG`	`@0 Endoscopy @5 17`
C03	`11`	`X`	`SPA`	`@0 Endoscopía @5 17`
C03	`12`	`X`	`FRE`	`@0 Ganglion lymphatique @5 18`
C03	`12`	`X`	`ENG`	`@0 Lymph node @5 18`
C03	`12`	`X`	`SPA`	`@0 Ganglio linfático @5 18`
C03	`13`	`X`	`FRE`	`@0 Excision @5 19`
C03	`13`	`X`	`ENG`	`@0 Excision @5 19`
C03	`13`	`X`	`SPA`	`@0 Excisión @5 19`
C03	`14`	`X`	`FRE`	`@0 Méthodologie @5 20`
C03	`14`	`X`	`ENG`	`@0 Methodology @5 20`
C03	`14`	`X`	`SPA`	`@0 Metodología @5 20`
C03	`15`	`X`	`FRE`	`@0 Procédure @5 21`
C03	`15`	`X`	`ENG`	`@0 Procedure @5 21`
C03	`15`	`X`	`SPA`	`@0 Procedimiento @5 21`
C03	`16`	`X`	`FRE`	`@0 Néphrologie @5 22`
C03	`16`	`X`	`ENG`	`@0 Nephrology @5 22`
C03	`16`	`X`	`SPA`	`@0 Nefrología @5 22`
C03	`17`	`X`	`FRE`	`@0 Urologie @5 23`
C03	`17`	`X`	`ENG`	`@0 Urology @5 23`
C03	`17`	`X`	`SPA`	`@0 Urología @5 23`
C03	`18`	`X`	`FRE`	`@0 Traitement @5 25`
C03	`18`	`X`	`ENG`	`@0 Treatment @5 25`
C03	`18`	`X`	`SPA`	`@0 Tratamiento @5 25`
C07	`01`	`X`	`FRE`	`@0 Pathologie de l'appareil génital mâle @5 37`
C07	`01`	`X`	`ENG`	`@0 Male genital diseases @5 37`
C07	`01`	`X`	`SPA`	`@0 Aparato genital macho patología @5 37`
C07	`02`	`X`	`FRE`	`@0 Pathologie de l'appareil urinaire @5 38`
C07	`02`	`X`	`ENG`	`@0 Urinary system disease @5 38`
C07	`02`	`X`	`SPA`	`@0 Aparato urinario patología @5 38`
C07	`03`	`X`	`FRE`	`@0 Tumeur maligne @2 NM @5 39`
C07	`03`	`X`	`ENG`	`@0 Malignant tumor @2 NM @5 39`
C07	`03`	`X`	`SPA`	`@0 Tumor maligno @2 NM @5 39`
C07	`04`	`X`	`FRE`	`@0 Cancer @2 NM`
C07	`04`	`X`	`ENG`	`@0 Cancer @2 NM`
C07	`04`	`X`	`SPA`	`@0 Cáncer @2 NM`
C07	`05`	`X`	`FRE`	`@0 Pathologie de la prostate @5 40`
C07	`05`	`X`	`ENG`	`@0 Prostate disease @5 40`
C07	`05`	`X`	`SPA`	`@0 Prostata patología @5 40`
N21				`@1 117`
N44	`01`			`@1 OTO`
N82				`@1 OTO`

Format Inist (serveur)

NO :	PASCAL 09-0161374 INIST
ET :	Robotic-Assisted Laparoscopic Extended Pelvic Lymph Node Dissection for Prostate Cancer : Surgical Technique and Experience with the First 99 Cases. Commentaries
AU :	FEICKE (Antje); BAUMGARTNER (Martin); TALIMI (Scherwin); SCHMID (Daniel Max); SEIFERT (Hans-Helge); MÜNTENER (Michael); FATZER (Markus); SULSER (Tullio); STREBEL (Rdto T.); MOTTRIE (Alexandre); TOUIJER (Karim)
AF :	Department of Urology, University Hospital Zürich, University of Zürich/Zürich/Suisse (1 aut., 2 aut., 3 aut., 4 aut., 5 aut., 6 aut., 7 aut., 8 aut., 9 aut.); O.L.V. Clinic/Aalst/Belgique (10 aut.); Department of Surgery, Urology Service, Memorial Sioan-Kettering Cancer Center/New York/Etats-Unis (11 aut.)
DT :	Publication en série; Article; Commentaire; Niveau analytique
SO :	European urology; ISSN 0302-2838; Coden EUURAV; Royaume-Uni; Da. 2009; Vol. 55; No. 4; Pp. 876-884; Bibl. 36 ref.
LA :	Anglais
EA :	Background: To date, there is still a paucity of data in the literature on robotic-assisted laparoscopic extended pelvic lymph node dissection (RALEPLND) in patients with prostate cancer. Objective: To assess the technical feasibility of RALEPLND and to present our surgical technique. Design, setting, and participants: From April 2006 to March 2008, we performed RALEPLND in 99 patients prior to robotic-assisted laparoscopic radical prostatectomy. Indications for RALEPLND were a prostate-specific antigen (PSA) >10 ng/ml or a preoperative Gleason score >7. The data were evaluated retrospectively. Surgical procedure: The transperitoneal approach was used in all cases. In order to gain optimal access to the common iliac bifurcation, the five trocars were placed in a more cephalad position than in patients undergoing radical prostatectomy without RALEPLND. After identification of important landmarks, the lymphatics covering the external iliac vein, the obturator lymphatic packet, and the lymphatics overlying the internal iliac artery were removed on both sides. Measurements: The total lymph node yield, the frequency of lymph node metastases, and the complication rate. Results and limitations: The median patient age was 64 yr (range: 45-78). The median preoperative PSA level was 7.7 ng/ml (range: 1.5-84.6). The median number of lymph nodes harvested was 19 (range: 8-53). In 16 patients (16%), we found lymph node metastasis. Complications occurred in seven patients (7%). Conclusions: RALEPLND is feasible, and its lymph node yield is well in the range of open series. The robotic-assisted laparoscopic approach in itself does not seem to limit a surgeon's ability to perform a complete extended pelvic lymph node dissection.
CC :	002B14D02; 002B20B02
FD :	Cancer de la prostate; Robotique; Télémédecine; Tumeur de la prostate; Laparoscopie; Ganglion pelvien; Lymphadénectomie; Chirurgie; Technique; Complication; Endoscopie; Ganglion lymphatique; Excision; Méthodologie; Procédure; Néphrologie; Urologie; Traitement
FG :	Pathologie de l'appareil génital mâle; Pathologie de l'appareil urinaire; Tumeur maligne; Cancer; Pathologie de la prostate
ED :	Prostate cancer; Robotics; Telemedicine; Prostate tumor; Laparoscopy; Pelvic ganglion; Lymphadenectomy; Surgery; Technique; Complication; Endoscopy; Lymph node; Excision; Methodology; Procedure; Nephrology; Urology; Treatment
EG :	Male genital diseases; Urinary system disease; Malignant tumor; Cancer; Prostate disease
SD :	Cáncer de la próstata; Robótica; Telemedicina; Tumor prostata; Laparoscopia; Ganglio pelviano; Linfadenectomía; Cirugía; Técnica; Complicación; Endoscopía; Ganglio linfático; Excisión; Metodología; Procedimiento; Nefrología; Urología; Tratamiento
LO :	INIST-16847.354000187052290140
ID :	09-0161374

Links to Exploration step

Pascal:09-0161374

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Robotic-Assisted Laparoscopic Extended Pelvic Lymph Node Dissection for Prostate Cancer : Surgical Technique and Experience with the First 99 Cases. Commentaries</title>
<author><name sortKey="Feicke, Antje" sort="Feicke, Antje" uniqKey="Feicke A" first="Antje" last="Feicke">Antje Feicke</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Urology, University Hospital Zürich, University of Zürich</s1>
<s2>Zürich</s2>
<s3>CHE</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Baumgartner, Martin" sort="Baumgartner, Martin" uniqKey="Baumgartner M" first="Martin" last="Baumgartner">Martin Baumgartner</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Urology, University Hospital Zürich, University of Zürich</s1>
<s2>Zürich</s2>
<s3>CHE</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Talimi, Scherwin" sort="Talimi, Scherwin" uniqKey="Talimi S" first="Scherwin" last="Talimi">Scherwin Talimi</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Urology, University Hospital Zürich, University of Zürich</s1>
<s2>Zürich</s2>
<s3>CHE</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Schmid, Daniel Max" sort="Schmid, Daniel Max" uniqKey="Schmid D" first="Daniel Max" last="Schmid">Daniel Max Schmid</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Urology, University Hospital Zürich, University of Zürich</s1>
<s2>Zürich</s2>
<s3>CHE</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Seifert, Hans Helge" sort="Seifert, Hans Helge" uniqKey="Seifert H" first="Hans-Helge" last="Seifert">Hans-Helge Seifert</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Urology, University Hospital Zürich, University of Zürich</s1>
<s2>Zürich</s2>
<s3>CHE</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Muntener, Michael" sort="Muntener, Michael" uniqKey="Muntener M" first="Michael" last="Müntener">Michael Müntener</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Urology, University Hospital Zürich, University of Zürich</s1>
<s2>Zürich</s2>
<s3>CHE</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Fatzer, Markus" sort="Fatzer, Markus" uniqKey="Fatzer M" first="Markus" last="Fatzer">Markus Fatzer</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Urology, University Hospital Zürich, University of Zürich</s1>
<s2>Zürich</s2>
<s3>CHE</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Sulser, Tullio" sort="Sulser, Tullio" uniqKey="Sulser T" first="Tullio" last="Sulser">Tullio Sulser</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Urology, University Hospital Zürich, University of Zürich</s1>
<s2>Zürich</s2>
<s3>CHE</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Strebel, Rdto T" sort="Strebel, Rdto T" uniqKey="Strebel R" first="Rdto T." last="Strebel">Rdto T. Strebel</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Urology, University Hospital Zürich, University of Zürich</s1>
<s2>Zürich</s2>
<s3>CHE</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Mottrie, Alexandre" sort="Mottrie, Alexandre" uniqKey="Mottrie A" first="Alexandre" last="Mottrie">Alexandre Mottrie</name>
<affiliation><inist:fA14 i1="02"><s1>O.L.V. Clinic</s1>
<s2>Aalst</s2>
<s3>BEL</s3>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Touijer, Karim" sort="Touijer, Karim" uniqKey="Touijer K" first="Karim" last="Touijer">Karim Touijer</name>
<affiliation><inist:fA14 i1="03"><s1>Department of Surgery, Urology Service, Memorial Sioan-Kettering Cancer Center</s1>
<s2>New York</s2>
<s3>USA</s3>
<sZ>11 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">09-0161374</idno>
<date when="2009">2009</date>
<idno type="stanalyst">PASCAL 09-0161374 INIST</idno>
<idno type="RBID">Pascal:09-0161374</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000064</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Robotic-Assisted Laparoscopic Extended Pelvic Lymph Node Dissection for Prostate Cancer : Surgical Technique and Experience with the First 99 Cases. Commentaries</title>
<author><name sortKey="Feicke, Antje" sort="Feicke, Antje" uniqKey="Feicke A" first="Antje" last="Feicke">Antje Feicke</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Urology, University Hospital Zürich, University of Zürich</s1>
<s2>Zürich</s2>
<s3>CHE</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Baumgartner, Martin" sort="Baumgartner, Martin" uniqKey="Baumgartner M" first="Martin" last="Baumgartner">Martin Baumgartner</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Urology, University Hospital Zürich, University of Zürich</s1>
<s2>Zürich</s2>
<s3>CHE</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Talimi, Scherwin" sort="Talimi, Scherwin" uniqKey="Talimi S" first="Scherwin" last="Talimi">Scherwin Talimi</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Urology, University Hospital Zürich, University of Zürich</s1>
<s2>Zürich</s2>
<s3>CHE</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Schmid, Daniel Max" sort="Schmid, Daniel Max" uniqKey="Schmid D" first="Daniel Max" last="Schmid">Daniel Max Schmid</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Urology, University Hospital Zürich, University of Zürich</s1>
<s2>Zürich</s2>
<s3>CHE</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Seifert, Hans Helge" sort="Seifert, Hans Helge" uniqKey="Seifert H" first="Hans-Helge" last="Seifert">Hans-Helge Seifert</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Urology, University Hospital Zürich, University of Zürich</s1>
<s2>Zürich</s2>
<s3>CHE</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Muntener, Michael" sort="Muntener, Michael" uniqKey="Muntener M" first="Michael" last="Müntener">Michael Müntener</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Urology, University Hospital Zürich, University of Zürich</s1>
<s2>Zürich</s2>
<s3>CHE</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Fatzer, Markus" sort="Fatzer, Markus" uniqKey="Fatzer M" first="Markus" last="Fatzer">Markus Fatzer</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Urology, University Hospital Zürich, University of Zürich</s1>
<s2>Zürich</s2>
<s3>CHE</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Sulser, Tullio" sort="Sulser, Tullio" uniqKey="Sulser T" first="Tullio" last="Sulser">Tullio Sulser</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Urology, University Hospital Zürich, University of Zürich</s1>
<s2>Zürich</s2>
<s3>CHE</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Strebel, Rdto T" sort="Strebel, Rdto T" uniqKey="Strebel R" first="Rdto T." last="Strebel">Rdto T. Strebel</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Urology, University Hospital Zürich, University of Zürich</s1>
<s2>Zürich</s2>
<s3>CHE</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Mottrie, Alexandre" sort="Mottrie, Alexandre" uniqKey="Mottrie A" first="Alexandre" last="Mottrie">Alexandre Mottrie</name>
<affiliation><inist:fA14 i1="02"><s1>O.L.V. Clinic</s1>
<s2>Aalst</s2>
<s3>BEL</s3>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Touijer, Karim" sort="Touijer, Karim" uniqKey="Touijer K" first="Karim" last="Touijer">Karim Touijer</name>
<affiliation><inist:fA14 i1="03"><s1>Department of Surgery, Urology Service, Memorial Sioan-Kettering Cancer Center</s1>
<s2>New York</s2>
<s3>USA</s3>
<sZ>11 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">European urology</title>
<title level="j" type="abbreviated">Eur. urol.</title>
<idno type="ISSN">0302-2838</idno>
<imprint><date when="2009">2009</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">European urology</title>
<title level="j" type="abbreviated">Eur. urol.</title>
<idno type="ISSN">0302-2838</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Complication</term>
<term>Endoscopy</term>
<term>Excision</term>
<term>Laparoscopy</term>
<term>Lymph node</term>
<term>Lymphadenectomy</term>
<term>Methodology</term>
<term>Nephrology</term>
<term>Pelvic ganglion</term>
<term>Procedure</term>
<term>Prostate cancer</term>
<term>Prostate tumor</term>
<term>Robotics</term>
<term>Surgery</term>
<term>Technique</term>
<term>Telemedicine</term>
<term>Treatment</term>
<term>Urology</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Cancer de la prostate</term>
<term>Robotique</term>
<term>Télémédecine</term>
<term>Tumeur de la prostate</term>
<term>Laparoscopie</term>
<term>Ganglion pelvien</term>
<term>Lymphadénectomie</term>
<term>Chirurgie</term>
<term>Technique</term>
<term>Complication</term>
<term>Endoscopie</term>
<term>Ganglion lymphatique</term>
<term>Excision</term>
<term>Méthodologie</term>
<term>Procédure</term>
<term>Néphrologie</term>
<term>Urologie</term>
<term>Traitement</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Background: To date, there is still a paucity of data in the literature on robotic-assisted laparoscopic extended pelvic lymph node dissection (RALEPLND) in patients with prostate cancer. Objective: To assess the technical feasibility of RALEPLND and to present our surgical technique. Design, setting, and participants: From April 2006 to March 2008, we performed RALEPLND in 99 patients prior to robotic-assisted laparoscopic radical prostatectomy. Indications for RALEPLND were a prostate-specific antigen (PSA) >10 ng/ml or a preoperative Gleason score >7. The data were evaluated retrospectively. Surgical procedure: The transperitoneal approach was used in all cases. In order to gain optimal access to the common iliac bifurcation, the five trocars were placed in a more cephalad position than in patients undergoing radical prostatectomy without RALEPLND. After identification of important landmarks, the lymphatics covering the external iliac vein, the obturator lymphatic packet, and the lymphatics overlying the internal iliac artery were removed on both sides. Measurements: The total lymph node yield, the frequency of lymph node metastases, and the complication rate. Results and limitations: The median patient age was 64 yr (range: 45-78). The median preoperative PSA level was 7.7 ng/ml (range: 1.5-84.6). The median number of lymph nodes harvested was 19 (range: 8-53). In 16 patients (16%), we found lymph node metastasis. Complications occurred in seven patients (7%). Conclusions: RALEPLND is feasible, and its lymph node yield is well in the range of open series. The robotic-assisted laparoscopic approach in itself does not seem to limit a surgeon's ability to perform a complete extended pelvic lymph node dissection.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0302-2838</s0>
</fA01>
<fA02 i1="01"><s0>EUURAV</s0>
</fA02>
<fA03 i2="1"><s0>Eur. urol.</s0>
</fA03>
<fA05><s2>55</s2>
</fA05>
<fA06><s2>4</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Robotic-Assisted Laparoscopic Extended Pelvic Lymph Node Dissection for Prostate Cancer : Surgical Technique and Experience with the First 99 Cases. Commentaries</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>FEICKE (Antje)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>BAUMGARTNER (Martin)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>TALIMI (Scherwin)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>SCHMID (Daniel Max)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>SEIFERT (Hans-Helge)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>MÜNTENER (Michael)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>FATZER (Markus)</s1>
</fA11>
<fA11 i1="08" i2="1"><s1>SULSER (Tullio)</s1>
</fA11>
<fA11 i1="09" i2="1"><s1>STREBEL (Rdto T.)</s1>
</fA11>
<fA11 i1="10" i2="1"><s1>MOTTRIE (Alexandre)</s1>
<s9>comment.</s9>
</fA11>
<fA11 i1="11" i2="1"><s1>TOUIJER (Karim)</s1>
<s9>comment.</s9>
</fA11>
<fA14 i1="01"><s1>Department of Urology, University Hospital Zürich, University of Zürich</s1>
<s2>Zürich</s2>
<s3>CHE</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>O.L.V. Clinic</s1>
<s2>Aalst</s2>
<s3>BEL</s3>
<sZ>10 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Department of Surgery, Urology Service, Memorial Sioan-Kettering Cancer Center</s1>
<s2>New York</s2>
<s3>USA</s3>
<sZ>11 aut.</sZ>
</fA14>
<fA20><s1>876-884</s1>
</fA20>
<fA21><s1>2009</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>16847</s2>
<s5>354000187052290140</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2009 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>36 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>09-0161374</s0>
</fA47>
<fA60><s1>P</s1>
<s3>AR</s3>
<s3>CT</s3>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>European urology</s0>
</fA64>
<fA66 i1="01"><s0>GBR</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Background: To date, there is still a paucity of data in the literature on robotic-assisted laparoscopic extended pelvic lymph node dissection (RALEPLND) in patients with prostate cancer. Objective: To assess the technical feasibility of RALEPLND and to present our surgical technique. Design, setting, and participants: From April 2006 to March 2008, we performed RALEPLND in 99 patients prior to robotic-assisted laparoscopic radical prostatectomy. Indications for RALEPLND were a prostate-specific antigen (PSA) >10 ng/ml or a preoperative Gleason score >7. The data were evaluated retrospectively. Surgical procedure: The transperitoneal approach was used in all cases. In order to gain optimal access to the common iliac bifurcation, the five trocars were placed in a more cephalad position than in patients undergoing radical prostatectomy without RALEPLND. After identification of important landmarks, the lymphatics covering the external iliac vein, the obturator lymphatic packet, and the lymphatics overlying the internal iliac artery were removed on both sides. Measurements: The total lymph node yield, the frequency of lymph node metastases, and the complication rate. Results and limitations: The median patient age was 64 yr (range: 45-78). The median preoperative PSA level was 7.7 ng/ml (range: 1.5-84.6). The median number of lymph nodes harvested was 19 (range: 8-53). In 16 patients (16%), we found lymph node metastasis. Complications occurred in seven patients (7%). Conclusions: RALEPLND is feasible, and its lymph node yield is well in the range of open series. The robotic-assisted laparoscopic approach in itself does not seem to limit a surgeon's ability to perform a complete extended pelvic lymph node dissection.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B14D02</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B20B02</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Cancer de la prostate</s0>
<s2>NM</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Prostate cancer</s0>
<s2>NM</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Cáncer de la próstata</s0>
<s2>NM</s2>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Robotique</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Robotics</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Robótica</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Télémédecine</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Telemedicine</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Telemedicina</s0>
<s5>03</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Tumeur de la prostate</s0>
<s2>NM</s2>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Prostate tumor</s0>
<s2>NM</s2>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Tumor prostata</s0>
<s2>NM</s2>
<s5>04</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Laparoscopie</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Laparoscopy</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Laparoscopia</s0>
<s5>05</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Ganglion pelvien</s0>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Pelvic ganglion</s0>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Ganglio pelviano</s0>
<s5>06</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Lymphadénectomie</s0>
<s5>08</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Lymphadenectomy</s0>
<s5>08</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Linfadenectomía</s0>
<s5>08</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Chirurgie</s0>
<s5>09</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Surgery</s0>
<s5>09</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Cirugía</s0>
<s5>09</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Technique</s0>
<s5>11</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>Technique</s0>
<s5>11</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>Técnica</s0>
<s5>11</s5>
</fC03>
<fC03 i1="10" i2="X" l="FRE"><s0>Complication</s0>
<s5>12</s5>
</fC03>
<fC03 i1="10" i2="X" l="ENG"><s0>Complication</s0>
<s5>12</s5>
</fC03>
<fC03 i1="10" i2="X" l="SPA"><s0>Complicación</s0>
<s5>12</s5>
</fC03>
<fC03 i1="11" i2="X" l="FRE"><s0>Endoscopie</s0>
<s5>17</s5>
</fC03>
<fC03 i1="11" i2="X" l="ENG"><s0>Endoscopy</s0>
<s5>17</s5>
</fC03>
<fC03 i1="11" i2="X" l="SPA"><s0>Endoscopía</s0>
<s5>17</s5>
</fC03>
<fC03 i1="12" i2="X" l="FRE"><s0>Ganglion lymphatique</s0>
<s5>18</s5>
</fC03>
<fC03 i1="12" i2="X" l="ENG"><s0>Lymph node</s0>
<s5>18</s5>
</fC03>
<fC03 i1="12" i2="X" l="SPA"><s0>Ganglio linfático</s0>
<s5>18</s5>
</fC03>
<fC03 i1="13" i2="X" l="FRE"><s0>Excision</s0>
<s5>19</s5>
</fC03>
<fC03 i1="13" i2="X" l="ENG"><s0>Excision</s0>
<s5>19</s5>
</fC03>
<fC03 i1="13" i2="X" l="SPA"><s0>Excisión</s0>
<s5>19</s5>
</fC03>
<fC03 i1="14" i2="X" l="FRE"><s0>Méthodologie</s0>
<s5>20</s5>
</fC03>
<fC03 i1="14" i2="X" l="ENG"><s0>Methodology</s0>
<s5>20</s5>
</fC03>
<fC03 i1="14" i2="X" l="SPA"><s0>Metodología</s0>
<s5>20</s5>
</fC03>
<fC03 i1="15" i2="X" l="FRE"><s0>Procédure</s0>
<s5>21</s5>
</fC03>
<fC03 i1="15" i2="X" l="ENG"><s0>Procedure</s0>
<s5>21</s5>
</fC03>
<fC03 i1="15" i2="X" l="SPA"><s0>Procedimiento</s0>
<s5>21</s5>
</fC03>
<fC03 i1="16" i2="X" l="FRE"><s0>Néphrologie</s0>
<s5>22</s5>
</fC03>
<fC03 i1="16" i2="X" l="ENG"><s0>Nephrology</s0>
<s5>22</s5>
</fC03>
<fC03 i1="16" i2="X" l="SPA"><s0>Nefrología</s0>
<s5>22</s5>
</fC03>
<fC03 i1="17" i2="X" l="FRE"><s0>Urologie</s0>
<s5>23</s5>
</fC03>
<fC03 i1="17" i2="X" l="ENG"><s0>Urology</s0>
<s5>23</s5>
</fC03>
<fC03 i1="17" i2="X" l="SPA"><s0>Urología</s0>
<s5>23</s5>
</fC03>
<fC03 i1="18" i2="X" l="FRE"><s0>Traitement</s0>
<s5>25</s5>
</fC03>
<fC03 i1="18" i2="X" l="ENG"><s0>Treatment</s0>
<s5>25</s5>
</fC03>
<fC03 i1="18" i2="X" l="SPA"><s0>Tratamiento</s0>
<s5>25</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Pathologie de l'appareil génital mâle</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Male genital diseases</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Aparato genital macho patología</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Pathologie de l'appareil urinaire</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Urinary system disease</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Aparato urinario patología</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Tumeur maligne</s0>
<s2>NM</s2>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Malignant tumor</s0>
<s2>NM</s2>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Tumor maligno</s0>
<s2>NM</s2>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Cancer</s0>
<s2>NM</s2>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Cancer</s0>
<s2>NM</s2>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Cáncer</s0>
<s2>NM</s2>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Pathologie de la prostate</s0>
<s5>40</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Prostate disease</s0>
<s5>40</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Prostata patología</s0>
<s5>40</s5>
</fC07>
<fN21><s1>117</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
<server><NO>PASCAL 09-0161374 INIST</NO>
<ET>Robotic-Assisted Laparoscopic Extended Pelvic Lymph Node Dissection for Prostate Cancer : Surgical Technique and Experience with the First 99 Cases. Commentaries</ET>
<AU>FEICKE (Antje); BAUMGARTNER (Martin); TALIMI (Scherwin); SCHMID (Daniel Max); SEIFERT (Hans-Helge); MÜNTENER (Michael); FATZER (Markus); SULSER (Tullio); STREBEL (Rdto T.); MOTTRIE (Alexandre); TOUIJER (Karim)</AU>
<AF>Department of Urology, University Hospital Zürich, University of Zürich/Zürich/Suisse (1 aut., 2 aut., 3 aut., 4 aut., 5 aut., 6 aut., 7 aut., 8 aut., 9 aut.); O.L.V. Clinic/Aalst/Belgique (10 aut.); Department of Surgery, Urology Service, Memorial Sioan-Kettering Cancer Center/New York/Etats-Unis (11 aut.)</AF>
<DT>Publication en série; Article; Commentaire; Niveau analytique</DT>
<SO>European urology; ISSN 0302-2838; Coden EUURAV; Royaume-Uni; Da. 2009; Vol. 55; No. 4; Pp. 876-884; Bibl. 36 ref.</SO>
<LA>Anglais</LA>
<EA>Background: To date, there is still a paucity of data in the literature on robotic-assisted laparoscopic extended pelvic lymph node dissection (RALEPLND) in patients with prostate cancer. Objective: To assess the technical feasibility of RALEPLND and to present our surgical technique. Design, setting, and participants: From April 2006 to March 2008, we performed RALEPLND in 99 patients prior to robotic-assisted laparoscopic radical prostatectomy. Indications for RALEPLND were a prostate-specific antigen (PSA) >10 ng/ml or a preoperative Gleason score >7. The data were evaluated retrospectively. Surgical procedure: The transperitoneal approach was used in all cases. In order to gain optimal access to the common iliac bifurcation, the five trocars were placed in a more cephalad position than in patients undergoing radical prostatectomy without RALEPLND. After identification of important landmarks, the lymphatics covering the external iliac vein, the obturator lymphatic packet, and the lymphatics overlying the internal iliac artery were removed on both sides. Measurements: The total lymph node yield, the frequency of lymph node metastases, and the complication rate. Results and limitations: The median patient age was 64 yr (range: 45-78). The median preoperative PSA level was 7.7 ng/ml (range: 1.5-84.6). The median number of lymph nodes harvested was 19 (range: 8-53). In 16 patients (16%), we found lymph node metastasis. Complications occurred in seven patients (7%). Conclusions: RALEPLND is feasible, and its lymph node yield is well in the range of open series. The robotic-assisted laparoscopic approach in itself does not seem to limit a surgeon's ability to perform a complete extended pelvic lymph node dissection.</EA>
<CC>002B14D02; 002B20B02</CC>
<FD>Cancer de la prostate; Robotique; Télémédecine; Tumeur de la prostate; Laparoscopie; Ganglion pelvien; Lymphadénectomie; Chirurgie; Technique; Complication; Endoscopie; Ganglion lymphatique; Excision; Méthodologie; Procédure; Néphrologie; Urologie; Traitement</FD>
<FG>Pathologie de l'appareil génital mâle; Pathologie de l'appareil urinaire; Tumeur maligne; Cancer; Pathologie de la prostate</FG>
<ED>Prostate cancer; Robotics; Telemedicine; Prostate tumor; Laparoscopy; Pelvic ganglion; Lymphadenectomy; Surgery; Technique; Complication; Endoscopy; Lymph node; Excision; Methodology; Procedure; Nephrology; Urology; Treatment</ED>
<EG>Male genital diseases; Urinary system disease; Malignant tumor; Cancer; Prostate disease</EG>
<SD>Cáncer de la próstata; Robótica; Telemedicina; Tumor prostata; Laparoscopia; Ganglio pelviano; Linfadenectomía; Cirugía; Técnica; Complicación; Endoscopía; Ganglio linfático; Excisión; Metodología; Procedimiento; Nefrología; Urología; Tratamiento</SD>
<LO>INIST-16847.354000187052290140</LO>
<ID>09-0161374</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Belgique/explor/OpenAccessBelV2/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000064 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 000064 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Belgique
   |area=    OpenAccessBelV2
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:09-0161374
   |texte=   Robotic-Assisted Laparoscopic Extended Pelvic Lymph Node Dissection for Prostate Cancer : Surgical Technique and Experience with the First 99 Cases. Commentaries
}}

This area was generated with Dilib version V0.6.25.
Data generation: Thu Dec 1 00:43:49 2016. Site generation: Wed Mar 6 14:51:30 2024

	Serveur d'exploration autour du libre accès en Belgique
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration autour du libre accès en Belgique

Robotic-Assisted Laparoscopic Extended Pelvic Lymph Node Dissection for Prostate Cancer : Surgical Technique and Experience with the First 99 Cases. Commentaries

Robotic-Assisted Laparoscopic Extended Pelvic Lymph Node Dissection for Prostate Cancer : Surgical Technique and Experience with the First 99 Cases. Commentaries

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri